Masimo Radical® with SET Better than Nellcor N-600 with OxiMax, GE TruSat at Measuring SpO2 during Motion, Low Perfusion June 25, 2012 Masimo (NASDAQ: MASI) announced today a new study in the Journal ...

Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...

IRVINE, CA--(Marketwired - May 6, 2014) - Masimo (NASDAQ: MASI) today announced that the largest-ever study of newborn screening for congenital heart disease (CHD) was published online by The Lancet.

At Mercy Hospital, the Masimo Radical-7 and Rad-87 devices continuously monitor oxygenation with Masimo SET pulse oximetry and breathing with RRa. Meanwhile, the Patient SafetyNet system facilitates ...

Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...

IRVINE, Calif., Aug. 7, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today a new study in the Journal of Anesthesia demonstrates that for fluid responsiveness assessment, Masimo's noninvasive ...

About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. The wearable device has earned FDA clearance for its medical applications, ...

Masimo CorporationMASI announced that it has amended its royalty agreement with Nellcor. The agreement was originally inked by the two parties in Jan 2006. Per the amended agreement, Medtronic will ...

IRVINE, Calif., June 25, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today a new study in the Journal of Clinical Anesthesia demonstrates the Masimo Radical® with Masimo SET® pulse oximetry ...

The authors stated that both PVI and SVV are "much more valuable for prediction of volume responsiveness than CVP" and that PVI "is of high value, especially regarding sensitivity and negative ...